Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative clinical, preclinical and non-clinical research to determine the potential of MDSCs as a target for host-directed therapeutics for tuberculosis in the context of HIV co-infection, and to better understand the role of host-induced immunosuppression in the progression of Mycobacterium tuberculosis pathogenesis.

Funding: $275,000 total

Duration: 2 years 

Research Authority due date: 10 days prior to submission

LOI (encouraged) due date: 8.12.19, 8.12.20, 10.12.21

Full proposal due date: 8.1.20, 8.1.21, 10.1.22